Versão HTML básica
380
Souza CA, Pagnano KB, Bendit I, Conchon M, Freitas CM, Coelho AM, Funke VA, Bernardo WM
Rev Bras Hematol Hemoter. 2012;34(5):367-82
((((Leukemia, Myelogenous, Chronic, BCR-ABL Positive
OR Leukemia, Myeloid, Philadelphia-Positive OR Leukemia,
Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR
Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic
OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous,
Chronic ORMyelogenous Leukemia, Ph1-Positive ORLeukemia,
Myeloid, Ph1 Positive OR Myelogenous Leukemia, Chronic
OR Myeloid Leukemia, Philadelphia-Positive OR Granulocytic
Leukemia, Chronic)) AND (Fusion Proteins, bcr-abl OR BCR-
ABL OR BCR/ABL OR 9q OR Philadelphia OR chromosome
9))) AND (prognos*[Title/Abstract] OR (first[Title/Abstract]
AND episode[Title/Abstract]) OR cohort[Title/Abstract])
PICO 4
Do cytogenetic abnormalities in addition to the Philadelphia
chromosome (Ph) at diagnosis have prognostic significance?
((Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR
Leukemia, Myeloid, Philadelphia-Positive OR Leukemia,
Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR
Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic
OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous,
Chronic OR Myelogenous Leukemia, Ph1-Positive OR Leukemia,
Myeloid, Ph1 Positive OR Myelogenous Leukemia, Chronic
OR Myeloid Leukemia, Philadelphia-Positive OR Granulocytic
Leukemia, Chronic) AND (Fusion Proteins, bcr-abl OR BCR-ABL
OR BCR/ABL OR 9q OR Philadelphia OR chromosome 9 OR
cytogenetic OR additional chromosome abnormalities ORACAs))
AND (prognos*[Title/Abstract] OR (first[Title/Abstract] AND
episode[Title/Abstract]) OR cohort[Title/Abstract])
PICO 5
Are the criteria of the World Health Organization (WHO)
comparable to other criteria to classify the CML phases
(chronic, accelerated and blast crisis phases)?
((Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR
Leukemia, Myeloid, Philadelphia-Positive OR Leukemia,
Granulocytic, Chronic ORMyeloid Leukemia, Chronic OR Chronic
Myeloid Leukemia OR Leukemia, Myelocytic, Chronic OR Chronic
Myelocytic Leukemia OR Leukemia, Myelogenous, Chronic OR
Myelogenous Leukemia, Ph1-Positive OR Leukemia, Myeloid,
Ph1 Positive OR Myelogenous Leukemia, Chronic OR Myeloid
Leukemia, Philadelphia-Positive OR Granulocytic Leukemia,
Chronic) AND (classification OR staging OR criteria) AND (World
Health Organization OR WHO) AND ((sensitiv*[Title/Abstract]
OR sensitivity and specificity[MeSH Terms] OR diagnos*[Title/
Abstract]
OR
diagnosis[MeSH:noexp]
OR
diagnostic
*[MeSH:noexp] OR diagnosis, differential[MeSH:noexp] OR
diagnosis[Subheading:noexp])) OR (prognos*[Title/Abstract] OR
(first[Title/Abstract] AND episode[Title/Abstract]) OR cohort[Title/
Abstract]) OR Investigative Techniques OR Comparative study)
PICO 6
Is it important to define risk to CML patients using the Sokal
and Hasford scores?
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR
Leukemia, Myeloid, Philadelphia-Positive OR Leukemia,
Granulocytic, ChronicORMyeloidLeukemia, ChronicORChronic
MyeloidLeukemiaORLeukemia,Myelocytic,ChronicORChronic
Myelocytic Leukemia OR Leukemia, Myelogenous, Chronic OR
Myelogenous Leukemia, Ph1-Positive OR Leukemia, Myeloid,
Ph1 Positive OR Myelogenous Leukemia, Chronic OR Myeloid
Leukemia, Philadelphia-Positive OR Granulocytic Leukemia,
Chronic)AND(SokalORHasford)AND((sensitiv*[Title/Abstract]
OR sensitivity and specificity[MeSH Terms] OR diagnos*[Title/
Abstract]
OR
diagnosis[MeSH:noexp]
OR
diagnostic
*[MeSH:noexp] OR diagnosis, differential[MeSH:noexp] OR
diagnosis[Subheading:noexp]) OR (prognos*[Title/Abstract]
OR (first[Title/Abstract] AND episode[Title/Abstract]) OR
cohort[Title/Abstract])) OR (evaluation study OR comparative
study OR epidemiologic methods))
PICO 7
Is imatinib better than second generation tyrosine kinase
inhibitors as first-line treatment of chronic phase CML?
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR
Leukemia, Myeloid, Philadelphia-Positive OR Leukemia,
Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR
Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic
OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous,
Chronic ORMyelogenous Leukemia, Ph1-Positive ORLeukemia,
Myeloid, Ph1 Positive OR Myelogenous Leukemia, Chronic
OR Myeloid Leukemia, Philadelphia-Positive OR Granulocytic
Leukemia, Chronic) AND (nilotinib OR dasatinib) AND imatinib
AND ((clinical[Title/Abstract] AND trial[Title/Abstract]) OR
clinical trials[MeSH Terms] OR clinical trial[Publication Type]
OR random*[Title/Abstract] OR random allocation[MeSH
Terms] OR therapeutic use[MeSH Subheading])
PICO 8
Does the time between diagnosis and start of treatment with
imatinib have prognostic importance?
(((((((Leukemia,
Myelogenous,
Chronic,
BCR-ABL
Positive OR Leukemia, Myeloid, Philadelphia-Positive OR
Leukemia, Granulocytic, Chronic OR Myeloid Leukemia,
Chronic OR Chronic Myeloid Leukemia OR Leukemia,
Myelocytic, Chronic OR Chronic Myelocytic Leukemia
OR Leukemia, Myelogenous, Chronic OR Myelogenous
Leukemia, Ph1-Positive OR Leukemia, Myeloid, Ph1
Positive OR Myelogenous Leukemia, Chronic OR Myeloid
Leukemia, Philadelphia-Positive OR Granulocytic Leukemia,
Chronic)) AND Imatinib) AND Prognosis/narrow[filter]))
OR ((((Leukemia, Myelogenous, Chronic, BCR-ABL
Positive OR Leukemia, Myeloid, Philadelphia-Positive OR
Leukemia, Granulocytic, Chronic OR Myeloid Leukemia,
Chronic OR Chronic Myeloid Leukemia OR Leukemia,
Myelocytic, Chronic OR Chronic Myelocytic Leukemia
OR Leukemia, Myelogenous, Chronic OR Myelogenous
Leukemia, Ph1-Positive OR Leukemia, Myeloid, Ph1 Positive
OR Myelogenous Leukemia, Chronic OR Myeloid Leukemia,